$2.29
arrow_drop_down2.34%Is SBFM a Buy or Sell based on AI Analysis?
Fundamental Analysis
Sunshine Biopharma's fundamental analysis reveals several key indicators that investors may consider when evaluating the company. Firstly, the company's market capitalization stands at $13.17 million, indicating its size in the market. Additionally, the company's low price-to-book ratio of 0.38 suggests that its stock may be undervalued in relation to its assets. Furthermore, the company's strong current ratio of 4.41 indicates that it has sufficient assets to cover its liabilities, providing a measure of its financial health. Additionally, the company's gross profit of $8.19 million highlights its ability to generate revenue from its core operations. Moreover, Sunshine Biopharma's negative net income of -$4.51 million and negative operating margin of -17.91% indicate that the company may be facing challenges in maintaining profitability and operational efficiency. Furthermore, the company's high debt-to-equity ratio of 0.02 suggests that it may be relying heavily on debt to finance its operations, which could pose financial risks in the long term. Additionally, the company's low return on equity of -18.48% may indicate that it is not effectively leveraging its equity to generate profits for shareholders. Overall, these fundamental indicators provide valuable insights into Sunshine Biopharma's financial performance and could help investors make informed decisions about investing in the company.
Positive Development
Sunshine Biopharma Inc has shown a strong asset turnover ratio, which indicates efficient use of assets in generating sales. The company has a high cash ratio, which suggests that it has sufficient liquidity to meet its financial obligations and invest in growth opportunities. The company's current ratio is also high, which indicates that it can pay its short-term liabilities without difficulty. The company has a low net debt to total capital ratio, indicating that its financial leverage is manageable.
Negative Development
The company's EBIT per share is negative, which suggests that the company might be experiencing operational difficulties and/or high costs. The company's EPS is also negative, which could indicate a decline in the company's profitability. The company's free cash flow per share is negative, which may indicate that the company is not generating enough cash to cover its expenses or invest in growth. The company's gross margin is low, which could suggest that the company is facing high production costs or inefficient operations.
Technical Analysis
Sunshine Biopharma (SBFM) has a technical rating of NEUTRAL, with technical indicators such as WILLR, RSI, MACD, CCI, ADX, ATR, and STOCHRSI showing a mixed outlook for the stock. The stock currently has a price of $0.31, with a 52-week high of $64.5 and a low of $0.28. The stock has experienced a significant decline in price over the past year, with a 52-week price change percent of -99.41%. Additionally, the stock has seen negative price changes in the short term, with a seven-day price change percent of -19.49%, a one-month price change percent of -64.72%, and a three-month price change percent of -94.13%. On the other hand, Sunshine Biopharma has shown some positive technical indicators, such as a long-term upward trendline with a slope of 0.44. The stock has also received a buy recommendation from analysts, with a forecasted price of $2.6, representing a significant upside potential of 728.03%. However, the stock has faced challenges in terms of technical resistance and support levels, with the longest support price at $0.05 and a 65-day support period. Overall, while the technical analysis indicates mixed signals for the stock, the positive long-term trendline and analyst forecast suggest potential growth opportunities for Sunshine Biopharma in the future.
Conclusion and recommendation
Sunshine Biopharma, a company in the healthcare sector, is currently trading at a price of $0.31 with a market cap of $13.17M. Despite a negative trend in price change over the past week and month, the company has a solid technical rating of NEUTRAL and a high market growth score of 90. With a strong emphasis on research and development, as evidenced by a 7.7% R&D ratio, Sunshine Biopharma shows potential for high growth in the future. Additionally, the company has a healthy current ratio of 4.41 and quick ratio of 3.23, indicating strong liquidity and ability to meet short-term obligations. In conclusion, Sunshine Biopharma presents itself as a high-value, high-growth stock with potential for long-term success. While the company has faced challenges in price performance in recent months, its focus on innovation and growth opportunities in the healthcare sector bode well for its future prospects. Investors may want to keep a close eye on the company's research and development efforts, as well as its ability to capitalize on market growth opportunities. Overall, Sunshine Biopharma's solid financial metrics and industry scores position it as a company with potential for future success in the stock market.